Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The drugmaker said that it would stop studying danuglipron after a participant in one of its trials experienced a possible ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

The new approach recommends focusing on quality of life and mental health — and even includes medications like GLP-1s, which include Ozempic for kids 12 and up when needed.

The drugmaker said it would stop studying danuglipron after a participant had a possible drug-induced liver injury.

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...